Trasplante pulmonar en pacientes portadores de fibrosis pulmonar: caracterización de una cohorte de 87 pacientes

Abstract

Lung transplantation in 87 patients with idiopathic pulmonary fibrosisPulmonary fibrosis is a progressive disease. Lung transplantation is the only effective therapy for a group of patients. Objective: To evaluate results of lung transplantation for fibrosis up to a 5 years of follow up. Methodology: Retrospective review of clinical records of patients subjected to lung transplantation from Clínica Las Condes and Instituto Nacional del Tórax. Demographic data, type of transplant, baseline and post-transplant spirometry and 6 min walked distance (6MWT), early and late complications and long-term survival rate were analyzed. Results: From 1999 to 2015, 87 patients with pulmonary fibrosis were transplanted, in average they were 56 years old, 56% were male, 89% of patients were subjected to a single lung transplant. 16% of them were in urgency. Baseline and 1-3-5 years for FVC were 49-73-83 and 78% of the reference values and for 6MWT were 280, 485, 531 and 468 meters respectively. Predominant complications < 1 year post-transplant were: acute rejection (30%) and infections (42%). Complications after 1 year of transplantation were chronic graft dysfunction (DCI) 57% and neoplasms (15%). The main causes of mortality > 1 year were DCI (45%) and neoplasms (11%). The estimated 1, 3 and 5 year survival rate were 84, 71 and 58% respectively. Conclusions: Lung transplantation in patients with pulmonary fibrosis improves their quality of life and survival rate. The monopulmonary technique is efficient in the long term. Acute rejection and infection were the most common early complications and chronic graft dysfunction was the prevalent long-term complication.

Trasplante pulmonar: una perspectiva desde la inmunología

“…Se describe que un 41,4% de los pacientes tendrían BOS a los 5 años y 67,1% a los 10 años, siendo la sobrevida media tras el diagnóstico de 3 a 5 años 3,20,26 . En una casuística chilena, se describe que lo presenta un 23% a los 3 años y 57% a los 5 años 27 .…”